The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
Open accessAbstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in the world. Metabolic reprogramming is considered a new hallmark of cancer, but it remains unclearly described in HCC. The dysregulation of the PI3K/AKT/mTOR signaling pathway is common in HCC and is, therefore, a topic of further research and the concern of developing a novel target for liver cancer therapy. In this review, we illustrate mechanisms by which this signaling network is accountable for regulating HCC cellular metabolism, including glucose metabolism, lipid metabolism, amino acid metabolism, pyrimidine metabolism, and oxidative metabolism, and summarize the ongoing clinical trials based on the inhibition of the PI3K/AKT/mTOR pathway in HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Metabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Hepatocellular carcinoma pathogenesis: from genes to environment
Farazi, P. A., & DePinho, R. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1934 · Cited by 1,979
Macrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837
Cancer metabolism: looking forward
Martínez-Reyes, I., & Chandel, N. S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,824
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 3×
“Activation of the PI3K/AKT signaling pathway leads to higher G6PD activity, thereby enhancing metabolic activities and promoting cancer cell growth [51].”
BackgroundInfluentialPI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology
Shimano, H., & Sato, R. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.91 · Cited by 1,174
Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization
Vergadi, E., Ieronymaki, E., Lyroni, K., Vaporidi, K., & Tsatsanis, C. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601515 · Cited by 1,148
Targeting metabolic transformation for cancer therapy
Tennant, D. A., Durán, R. V., & Gottlieb, E. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2817 · Cited by 1,059
Nogueira, V., Park, Y., Chen, C.-C., Xu, P.-Z., Chen, M.-L., Tonic, I., Unterman, T., & Hay, N. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.11.003 · Cited by 780
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 763
Differential regulation of mTORC1 by leucine and glutamine
Jewell, J. L., Kim, Y. C., Russell, R. C., Yu, F.-X., Park, H. W., Plouffe, S. W., Tagliabracci, V. S., & Guan, K.-L. (2015) · Science · doi:10.1126/science.1259472 · Cited by 757
Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1
Ben-Sahra, I., Howell, J. J., Asara, J. M., & Manning, B. D. (2013) · Science · doi:10.1126/science.1228792 · Cited by 739
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 733
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to Chemotherapy
Lee, C., Raffaghello, L., Brandhorst, S., Safdie, F. M., Bianchi, G., Martin-Montalvo, A., Pistoia, V., Wei, M., Hwang, S., Merlino, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003293 · Cited by 715
Calvisi, D. F., Wang, C., Ho, C., Ladu, S., Lee, S. A., Mattu, S., Destefanis, G., Delogu, S., Zimmermann, A., Ericsson, J., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.12.006 · Cited by 595
Regulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
Yang, P., Li, Q.-J., Feng, Y., Zhang, Y., Markowitz, G. J., Ning, S., Deng, Y., Zhao, J., Jiang, S., Yuan, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.023 · Cited by 536
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524
NK Cell Metabolism and Tumor Microenvironment
Terrén, I., Orrantia, A., Vitallé, J., Zenarruzabeitia, O., & Borrego, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02278 · Cited by 501
A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy
Ronan, B., Flamand, O., Vescovi, L., Dureuil, C., Durand, L., Fassy, F., Bachelot, M.-F., Lamberton, A., Mathieu, M., Bertrand, T., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1681 · Cited by 500
Fang, Y., Xue, J.-L., Shen, Q., Chen, J., & Tian, L. (2012) · Hepatology · doi:10.1002/hep.25576 · Cited by 425
Self-citationmTOR signaling and drug development in cancer
Dancey, J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.21 · Cited by 417
mTORC2 Promotes Tumorigenesis via Lipid Synthesis
Guri, Y., Colombi, M., Dazert, E., Hindupur, S. K., Roszik, J., Moes, S., Jenoe, P., Heim, M. H., Riezman, I., Riezman, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.011 · Cited by 407
Lim, S.-O., Gu, J.-M., Kim, M. S., Kim, H.-S., Park, Y. N., Park, C. K., Cho, J. W., Park, Y. M., & Jung, G. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.027 · Cited by 381
Loftus, R. M., Assmann, N., Kedia-Mehta, N., O’Brien, K. L., Garcia, A., Gillespie, C., Hukelmann, J. L., Oefner, P. J., Lamond, A. I., Gardiner, C. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04719-2 · Cited by 381
Liu, Y., Cheng, Y., Xu, Y., Wang, Z., Du, X., Li, C., Peng, J., Gao, L., Liang, X., & Ma, C. (2017) · Oncogene · doi:10.1038/onc.2017.209 · Cited by 366
Ma, J., Zheng, B., Goswami, S., Meng, L., Zhang, D., Cao, C., Li, T., Zhu, F., Ma, L., Zhang, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0814-7 · Cited by 360
Crompton, J. G., Sukumar, M., Roychoudhuri, R., Clever, D., Gros, A., Eil, R. L., Tran, E., Hanada, K.-I., Yu, Z., Palmer, D. C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2277 · Cited by 345
Lin, R., Elf, S., Shan, C., Kang, H.-B., Ji, Q., Zhou, L., Hitosugi, T., Zhang, L., Zhang, S., Seo, J. H., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3255 · Cited by 287
Wu, Q., Zhou, L., Lv, D., Zhu, X., & Tang, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0739-0 · Cited by 281
Macintyre, A. N., Finlay, D., Preston, G., Sinclair, L. V., Waugh, C. M., Tamas, P., Feijoo, C., Okkenhaug, K., & Cantrell, D. A. (2011) · Immunity · doi:10.1016/j.immuni.2011.01.012 · Cited by 273
The Role of mTOR Signaling as a Therapeutic Target in Cancer
Popova, N. V., & Jücker, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041743 · Cited by 267
Self-citationComparison of hepatocellular carcinoma in Eastern versus Western populations
Choo, S. P., Tan, W. L., Goh, B. K. P., Tai, W. M., & Zhu, A. X. (2016) · Cancer · doi:10.1002/cncr.30237 · Cited by 264
O-GlcNAcylation of G6PD promotes the pentose phosphate pathway and tumor growth
Rao, X., Duan, X., Mao, W., Li, X., Li, Z., Li, Q., Zheng, Z., Xu, H., Chen, M., Wang, P. G., et al. (2015) · Nature Communications · doi:10.1038/ncomms9468 · Cited by 257
Li, J., Huang, Q., Long, X., Zhang, J., Huang, X., Aa, J., Yang, H., Chen, Z., & Xing, J. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.039 · Cited by 256
Arginine Deprivation as a Targeted Therapy for Cancer
Feun, L., You, M., Wu, C., Kuo, M., Wangpaichitr, M., Spector, S., & Savaraj, N. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784246199 · Cited by 233
A non-proliferative role of pyrimidine metabolism in cancer
Siddiqui, A., & Ceppi, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.02.005 · Cited by 228
Metabolism, migration and memory in cytotoxic T cells
Finlay, D., & Cantrell, D. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri2888 · Cited by 225
Luo, X., Zheng, E., Wei, L., Zeng, H., Qin, H., Zhang, X., Liao, M., Chen, L., Zhao, L., Ruan, X. Z., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03596-w · Cited by 224
PI3K Inhibitors in Breast Cancer Therapy
Ellis, H., & Ma, C. X. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0846-7 · Cited by 219
Arsenene-mediated multiple independently targeted reactive oxygen species burst for cancer therapy
Kong, N., Zhang, H., Feng, C., Liu, C., Xiao, Y., Zhang, X., Mei, L., Kim, J. S., Tao, W., & Ji, X. (2021) · Nature Communications · doi:10.1038/s41467-021-24961-5 · Cited by 217
Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth
Cox, A. G., Hwang, K. L., Brown, K. K., Evason, K. J., Beltz, S., Tsomides, A., O’Connor, K., Galli, G. G., Yimlamai, D., Chhangawala, S., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3389 · Cited by 215
The Genomic Analysis of Lactic Acidosis and Acidosis Response in Human Cancers
Chen, J. L.-Y., Lucas, J. E., Schroeder, T., Mori, S., Wu, J., Nevins, J., Dewhirst, M., West, M., & Chi, J.-T. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000293 · Cited by 213
Bidkhori, G., Benfeitas, R., Klevstig, M., Zhang, C., Nielsen, J., Uhlen, M., Boren, J., & Mardinoglu, A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807305115 · Cited by 211
Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine
Wang, W., Cui, J., Ma, H., Lu, W., & Huang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684961 · Cited by 200
Targeting amino acid metabolism in cancer growth and anti-tumor immune response
Ananieva, E. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.281 · Cited by 197
Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells
Wang, X., Yang, K., Wu, Q., Kim, L. J. Y., Morton, A. R., Gimple, R. C., Prager, B. C., Shi, Y., Zhou, W., Bhargava, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau4972 · Cited by 193
Liver Damage, Inflammation, and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition
Umemura, A., Park, E. J., Taniguchi, K., Lee, J. H., Shalapour, S., Valasek, M. A., Aghajan, M., Nakagawa, H., Seki, E., Hall, M. N., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.001 · Cited by 183
Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
Asghar, U., & Meyer, T. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.031 · Cited by 182
Jin, H., Wang, S., Zaal, E. A., Wang, C., Wu, H., Bosma, A., Jochems, F., Isima, N., Jin, G., Lieftink, C., et al. (2020) · eLife · doi:10.7554/elife.56749 · Cited by 178
Impact of intracellular innate immune receptors on immunometabolism
Chou, W.-C., Rampanelli, E., Li, X., & Ting, J. P.-Y. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00780-y · Cited by 172
Zheng, Y.-L., Li, L., Jia, Y.-X., Zhang, B.-Z., Li, J.-C., Zhu, Y.-H., Li, M.-Q., He, J.-Z., Zeng, T.-T., Ban, X.-J., et al. (2019) · Theranostics · doi:10.7150/thno.28992 · Cited by 166
Lactic acid in macrophage polarization: The significant role in inflammation and cancer
Zhou, H.-C., Yan, X.-Y., Yu, W.-W., Liang, X.-Q., Du, X.-Y., Liu, Z.-C., Long, J.-P., Zhao, G.-H., & Liu, H.-B. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2021.1955876 · Cited by 165
TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism
Cheng, J., Huang, Y., Zhang, X., Yu, Y., Wu, S., Jiao, J., Tran, L. M., Zhang, W., Liu, R., Zhang, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15819-3 · Cited by 164
Class II PI3K Functions in Cell Biology and Disease
Gulluni, F., Santis, M. C. D., Margaria, J. P., Martini, M., & Hirsch, E. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.001 · Cited by 160
Huang, Q., Li, J., Xing, J., Li, W., Li, H., Ke, X., Zhang, J., Ren, T., Shang, Y., Yang, H., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.035 · Cited by 158
CARM1 Methylates GAPDH to Regulate Glucose Metabolism and Is Suppressed in Liver Cancer
Zhong, X.-Y., Yuan, X.-M., Xu, Y.-Y., Yin, M., Yan, W.-W., Zou, S.-W., Wei, L.-M., Lu, H.-J., Wang, Y.-P., & Lei, Q.-Y. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.066 · Cited by 158
Zhang, G., He, J., Ye, X., Zhu, J., Hu, X., Shen, M., Ma, Y., Mao, Z., Song, H., & Chen, F. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1492-6 · Cited by 156
IL-15–PI3K–AKT–mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells
Ali, A. K., Nandagopal, N., & Lee, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00355 · Cited by 153
Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans
Li, L., Pilo, G., Li, X., Cigliano, A., Latte, G., Che, L., Joseph, C., Mela, M., Wang, C., Jiang, L., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.004 · Cited by 153
Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma
Ferrín, G., Misas, M. G., Amado, V., Rodríguez‐Perálvarez, M., & de la Mata, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041266 · Cited by 148
The mTOR Pathway in Hepatic Malignancies
Bhat, M., Sonenberg, N., & Gores, G. J. (2013) · Hepatology · doi:10.1002/hep.26323 · Cited by 144
Liu, C., Gong, K., Mao, X., & Li, W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25817 · Cited by 140
Silva, A., Gírio, A., Cebola, I., Santos, C. I., Antunes, F., & Barata, J. T. (2011) · Leukemia · doi:10.1038/leu.2011.56 · Cited by 135
Chen, X., Li, L.-Y., Guan, Y.-D., Yang, J., & Cheng, Y. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.47 · Cited by 131
Grabinski, N., Ewald, F., Hofmann, B. T., Staufer, K., Schumacher, U., Nashan, B., & Jücker, M. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-85 · Cited by 129
Self-citationHu, J., Che, L., Li, L., Pilo, M. G., Cigliano, A., Ribback, S., Li, X., Latte, G., Mela, M., Evert, M., et al. (2016) · Scientific Reports · doi:10.1038/srep20484 · Cited by 129
Chai, Z., Kong, J., Zhu, X., Zhang, Y., Lu, L., Zhou, J., Wang, L., Zhang, K.-Z., Zhang, Q., Ao, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077957 · Cited by 127
Akt2 expression correlates with prognosis of human hepatocellular carcinoma
Xu, X., Sakon, M., Nagano, H., Hiraoka, N., Yamamoto, H., Hayashi, N., Dono, K., Nakamori, S., Umeshita, K., Ito, Y., et al. (2004) · Oncology Reports · doi:10.3892/or.11.1.25 · Cited by 121
Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms
Wang, Q., Yu, W.-N., Chen, X., Peng, X.-D., Jeon, S., Birnbaum, M. J., Guzman, G., & Hay, N. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.008 · Cited by 121
Targeting Lipid Metabolism in Liver Cancer
Alannan, M., Fayyad‐Kazan, H., Trézéguet, V., & Merched, A. J. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00477 · Cited by 119
He, F., Antonucci, L., Yamachika, S., Zhang, Z., Taniguchi, K., Umemura, A., Hatzivassiliou, G., Roose‐Girma, M., Reina‐Campos, M., Durán, Á., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.023 · Cited by 116
Saha, A., Connelly, S., Jiang, J., Zhuang, S., Amador, D., Phan, T., Pilz, R. B., & Boss, G. R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.028 · Cited by 113
Wei, Y., Tang, X., Ren, Y., Yang, Y. S., Song, F., Fu, J., Liu, S., Yu, M., Chen, J., Wang, S., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00801-2 · Cited by 108
The mTORC2‐Akt1 Cascade Is Crucial for c‐Myc to Promote Hepatocarcinogenesis in Mice and Humans
Xu, Z., Xu, M. M., Pin, L., Zhang, S., Shang, R., Qiao, Y., Che, L., Ribback, S., Cigliano, A., Evert, K., et al. (2019) · Hepatology · doi:10.1002/hep.30697 · Cited by 107
Galicia, V. A., He, L., Dang, H. T., Kanel, G. C., Vendryes, C., French, B. A., Zeng, N., Bayan, J., Ding, W., Wang, K. S., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.002 · Cited by 105
Li, L., Che, L., Tharp, K. M., Park, H., Pilo, M. G., Cao, D., Cigliano, A., Latte, G., Xu, Z., Ribback, S., et al. (2016) · Hepatology · doi:10.1002/hep.28508 · Cited by 105
Chen, J., Chen, J., Huang, J., Li, Z., Gong, Y., Zou, B., Liu, X., Ding, L., Li, P., Zhu, Z., et al. (2019) · Aging · doi:10.18632/aging.102488 · Cited by 105
Luo, Y., Fang, L., Yu, H., Zhang, J., Lin, X., Liu, X., Wu, D., Li, G.-X., Deng, H., Zhang, Y., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.036 · Cited by 104
Wan, J., Liu, T., Mei, L., Li, J., Gong, K., Yu, C., & Li, W. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.334 · Cited by 103
Golob‐Schwarzl, N., Krassnig, S., Toeglhofer, A. M., Park, Y. N., Gogg-Kamerer, M., Vierlinger, K., Schroeder, F., Rhee, H., Schicho, R., Fickert, P., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.003 · Cited by 102
Dimri, M., Humphries, A., Laknaur, A., Elattar, S., Lee, T. J., Sharma, A. K., Kolhe, R. B., & Ande, S. (2019) · Hepatology · doi:10.1002/hep.30818 · Cited by 99
Kim, Y.-S., Lee, Y.-M., Oh, T.-I., Shin, D. H., Kim, G.-H., Kan, S.-Y., Kang, H., Kim, J. H., Kim, B. M., Yim, W. J., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103127 · Cited by 97
Bort, A., Sánchez, B. G., Mateos‐Gómez, P. A., Díaz‐Laviada, I., & Rodríguez‐Henche, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071660 · Cited by 94
Metabolic tricks of cancer cells
Hönigová, K., Navrátil, J., Peltanová, B., Polanska, H. H., Raudenská, M., & Masařík, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188705 · Cited by 91
Zhang, Q., Lou, Y., Bai, X., & Liang, T. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i31.3500 · Cited by 87
Damodaran, S., Zhao, F., Deming, D. A., Mitchell, E. P., Wright, J. J., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L., Patton, D. R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01648 · Cited by 87
Rationalizing combination therapies
(2017) · Nature Medicine · doi:10.1038/nm.4426 · Cited by 84
Why Warburg Works: Lactate Controls Immune Evasion through GPR81
Lundø, K., Trauelsen, M., Pedersen, S. F., & Schwartz, T. W. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.03.001 · Cited by 82
Liu, G., Shi, A., Wang, N., Li, M., He, X., Yin, C., Tu, Q., Shen, X., Tao, Y., Wang, Q., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101701 · Cited by 81
Orci, L. A., Lacotte, S., Delaune, V., Slits, F., Oldani, G., Lazarević, V., Rossetti, C., Rubbia‐Brandt, L., Morel, P., & Toso, C. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.12.025 · Cited by 80
Zhangyuan, G., Wang, F., Zhang, H., Jiang, R., Tao, X., Yu, D., Jin, K., Yu, W., Liu, Y., Yin, Y., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1052-7 · Cited by 80
Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis
Facciorusso, A., Aziz, M. A. A. E., & Sacco, R. (2019) · Cancers · doi:10.3390/cancers12010036 · Cited by 78
Ren, T., Wang, J., Zhang, H., Yuan, P., Zhu, J., Wu, Y., Huang, Q., Guo, X., Zhang, J., Ji, L., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.6990 · Cited by 75
Ye, G., Qin, Y. W., Wang, S., Pan, D., Xu, S., Wu, C., Wang, X., Wang, J., Ye, H., & Shen, H. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1564558 · Cited by 75
Ye, L., Mayerle, J. V., Ziesch, A., Reiter, F. P., Gerbes, A. L., & Toni, E. N. D. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0165-7 · Cited by 70
GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway
Xi, J., Sun, Y., Zhang, M., Fa, Z., Wan, Y.-Y., Min, Z., Xu, H., Xu, C., & Tang, J. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.04.005 · Cited by 69
Ha, H. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i39.4932 · Cited by 68
Hu, J., Wei, H., Yao, K., Zhu, X., Chen, Z., & Ye, L. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i12.1492 · Cited by 67
Hu, C., Wu, D., Bao, L., Yin, T., Lei, D., Yu, J., & Tong, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.01.028 · Cited by 66
Zhu, Z., Cao, C., Zhang, D., Zhang, Z., Liu, L., Wu, D., & Sun, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04596-0 · Cited by 66
Basu, S., Hubbard, B., & Shevach, E. M. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.2ab0514-273rr · Cited by 64
Ko, E., Seo, H., & Jung, G. (2017) · Hepatology · doi:10.1002/hep.29604 · Cited by 60
Yin, F., Sharen, G., Yuan, F., Peng, Y., Chen, R., Zhou, X., Wei, H., Li, B., Jing, W., & Zhao, J. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.49 · Cited by 57
Knockdown of FOXK1 suppresses liver cancer cell viability by inhibiting glycolysis
Cui, H., Gao, Q., Zhang, L., Han, F., & Wang, L. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.10.018 · Cited by 56
Buontempo, F., Erşahin, T., Missiroli, S., Şentürk, Ş., Etro, D., Öztürk, M., Capitani, S., Çetin-Atalay, R., & Neri, L. M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9486-3 · Cited by 55
Shi, Z., Wulfkuhle, J. D., Nowicka, M., Gallagher, R. I., Saura, C., Nuciforo, P. G., Calvo, I., Andersen, J., Passos‐Coelho, J. L., Gil‐Gil, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2498 · Cited by 55
Yan, X., Huang, S., Yang, Y., Lu, Z., Li, F., Jiang, L., Jiang, Y., & Liu, J. (2021) · Liver Transplantation · doi:10.1002/lt.26387 · Cited by 55
Chong, Y. C., Toh, T. B., Chan, Z., Lin, Q. X. X., Thng, D. K. H., Hooi, L., Ding, Z., Shuen, T. W. H., Toh, H. C., Dan, Y. Y., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1559 · Cited by 53
Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma
Ridder, D. A., Schindeldecker, M., Weinmann, A., Berndt, K., Urbansky, L. L., Witzel, H. R., Heinrich, S., Roth, W., & Straub, B. K. (2021) · Cancers · doi:10.3390/cancers13040744 · Cited by 52
Icard, P., Simula, L., Wu, Z., Berzan, D., Sogni, P., Dohan, A. J. J., Dautry, R., Coquerel, A., Lincet, H., Loi, M., et al. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100790 · Cited by 52
Zheng, C., Liu, M., Ge, Y., Qian, Y., & Fan, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04563-9 · Cited by 50
Tong, M., Wong, T. L., Zhao, H., Zheng, Y., Xie, Y., Li, C.-H., Zhou, L., Che, N., Yun, J., Man, K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109617 · Cited by 49
Xia, Y., Brown, Z. J., Huang, H., & Tsung, A. (2021) · Cancer Medicine · doi:10.1002/cam4.4177 · Cited by 48
Liu, F., Wu, X., Qian, Y., Jiang, X. M., Wang, Y., & Gao, J. X. (2019) · Cell Death and Disease · doi:10.1038/s41419-020-2631-9 · Cited by 46
Yeh, Y., Ho, H., Wu, Y., Pan, C., Wang, Y., & Chou, T. (2019) · Modern Pathology · doi:10.1038/s41379-019-0357-y · Cited by 42
PET-Based Radiogenomics Supports mTOR Pathway Targeting for Hepatocellular Carcinoma
An, J., Oh, M., Kim, S.-Y., Oh, Y.-J., Oh, B., Oh, J.-H., Kim, W., Jung, J. H., Kim, H. I., Kim, J.-S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3208 · Cited by 39
Liu, Y., Zhao, Y., & Guo, L. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.11.002 · Cited by 37
Cai, J., Sun, X., Guo, H., Qu, X., Huang, H., Yu, C. J., Wu, H., Gao, Y., Kong, X., & Xia, Q. (2020) · Oncogenesis · doi:10.1038/s41389-020-00287-7 · Cited by 37
Ng, T., Yeung, O. W. H., Lam, Y. F., Liu, J., Liu, H., Pang, L., Yang, X. X., Zhu, J., Zhang, W., Lau, M. Y. H., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00569-y · Cited by 36
Fu, Y., Liu, S., Rodrigues, R. M., Han, Y., Guo, C., Zhu, Z., He, Y., Mackowiak, B., Feng, D., Gao, B., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.71134 · Cited by 30
Zhang, Y., Zhang, C., Zhao, Q., Wei, W., Dong, Z., Shao, L., Li, J., Wu, W. G., Zhang, H., Huang, H., et al. (2019) · PubMed · Cited by 29
Qiu, Z., Zhang, C., Zhou, J., Hu, J., Sheng, L., Li, X., Chen, L., Li, X., Deng, X., & Zheng, G. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22904 · Cited by 28
Lu, C., Yang, D., Klement, J. D., Colson, Y. L., Oberlies, N. H., Pearce, C. J., Colby, A. H., Grinstaff, M. W., Liu, Z., Shi, H., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02283-0 · Cited by 28
Xie, Z., Wang, J., Liu, M., Chen, D., Qiu, C., & Sun, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173252 · Cited by 27
Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma
Zecca, A., Barili, V., Canetti, D., Regina, V., Olivani, A., Carone, C., Capizzuto, V., Zerbato, B., Trenti, T., Valle, R. D., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02561-4 · Cited by 27
A combination of AZD5363 and FH5363 induces lethal autophagy in transformed hepatocytes
Patra, T., Meyer, K., Ray, R. B., & Ray, R. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02741-1 · Cited by 26
Ding, M., Bu, X., Li, Z., Xu, H., Feng, L., Hu, J., Wei, X., Gao, J., Tao, Y., Cai, B., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.48066 · Cited by 21
Zhao, Z., Gao, J., Li, C., Xu, X., Hu, Y., & Huang, S. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1621687 · Cited by 20
Xin, Z., Li, J., Zhang, H., Zhou, Y., Song, J., Chen, P., Bai, L., Chen, H., Zhou, J., Chen, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.783109 · Cited by 19
Wu, J., You, R.-I., Hu, C., Cheng, C.-C., Rudy, R., & Wu, W. (2019) · Oncogenesis · doi:10.1038/s41389-019-0149-8 · Cited by 17
Cheng, Y.-H., Ko, Y.-C., Ku, H., Huang, C.-C., Yao, Y.-C., Liao, Y.-T., Chen, Y.-T., Huang, S.-F. K., & Huang, L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.821224 · Cited by 8
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Metadata
- Authors
- Tian, L.-Y., Smit, D. J., & Jücker, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-01-31
- Volume
- 24
- Issue
- 3
- Pages
- 2652
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4318595810
- Cited by
- 329
- References
- 147
- FWCI
- 24.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.